{"nctId":"NCT04175834","briefTitle":"Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab","startDateStruct":{"date":"2020-02-05","type":"ACTUAL"},"conditions":["Multiple Sclerosis","Infusion Reaction"],"count":19,"armGroups":[{"label":"diphenhydramine","type":"OTHER","interventionNames":["Drug: diphenhydramine"]},{"label":"cetirizine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cetrizine"]}],"interventions":[{"name":"cetrizine","otherNames":["Active comparator"]},{"name":"diphenhydramine","otherNames":["Other"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female patient with relapsing or progressive forms of Multiple Sclerosis (MS), age 18 to 70 inclusive at the time of consent.\n2. Able to understand the purpose, responsibilities and risks of the study and provide signed informed consent.\n3. Naïve to ocrelizumab (OCR) and will receive OCR as part of standard of care for MS treatment.\n4. No evidence, in the opinion of the investigators of significant cognitive limitation or psychiatric disorder that would interfere with the conduct of the study.\n5. Estimated Expanded Disability Status Scale (EDSS) of ≤ 6.5 at screening.\n6. Female patients of childbearing potential must practice effective contraception and continue contraception during the study.\n\nExclusion Criteria:\n\n1. Any mental condition of such that patient is unable to understand the nature, scope, and possible consequences of the study.\n2. Evidence of active hepatitis B infection at screening.\n3. Patients with untreated hepatitis C, or tuberculosis. Patients who have history of Progressive multifocal leukoencephalopathy (PML) or known to be Human Immunodeficiency Virus (HIV) positive, per standard care.\n4. Any persistent or severe infection.\n5. Pregnancy or lactation.\n6. Significant, uncontrolled somatic disease or severe depression in the last year.\n7. Current use of immunosuppressive medication, lymphocyte-depleting agents, or lymphocyte-trafficking blockers.\n8. Patients with any significant comorbidity that in the opinion of the investigator, would interfere with participation in the study.\n9. Any known allergy or inability to tolerate diphenhydramine or cetirizine.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants With Infusion-related Reaction (IRR) on Day 0","description":"The proportion of patients having an infusion-related reaction (IRR), as defined by Common Terminology Criteria (CTCAE), version 4 during or after the first-half dose of the first infusion on day 0. IRRs are documented at the infusion clinic on the day of infusion and reported by the patient at the follow-up phone call the next business day after the infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Infusion-related Reaction (IRR) on Day 14","description":"The proportion of patients having an infusion-related reaction as defined by Common Terminology Criteria (CTCAE), version 4 during or after receiving the second half dose infusion on day 14","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With an Infusion-related Reaction (IRR) on Day 168","description":"The proportion of patients having an infusion-related reaction as defined by Common Terminology Criteria (CTCAE), version 4 during or after receiving the first full 600mg dose infusion on week 168","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Satisfaction Questionnaire for Medication (TSQM) Score on Days 0, 14 and 168","description":"Patient reported outcome on Treatment Satisfaction Questionnaire for Medication. TSQM is administered within 2 hours after ocrelizumab (OCR) infusion, may be completed via phone to assess patient treatment satisfaction for the infusion. TSQM covers four domains: Global satisfaction, Effectiveness, Side effects, and Convenience. The scores are calculated for each of the subscales, ranging from 0 to 100. Higher score indicates higher satisfaction of the participant with the treatment and lower score indicates lower satisfaction of the participant with the treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":"15.7"},{"groupId":"OG001","value":"90.8","spread":"9.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":"18.2"},{"groupId":"OG001","value":"86.7","spread":"11.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":"11.0"},{"groupId":"OG001","value":"100","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","spread":"13.9"},{"groupId":"OG001","value":"96.1","spread":"5.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":"14.7"},{"groupId":"OG001","value":"93.3","spread":"11.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.1","spread":"14.0"},{"groupId":"OG001","value":"91.9","spread":"14.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":"10.4"},{"groupId":"OG001","value":"100","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":"11.0"},{"groupId":"OG001","value":"96.6","spread":"7.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":"13.9"},{"groupId":"OG001","value":"99.1","spread":"2.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":"15.6"},{"groupId":"OG001","value":"93.5","spread":"10.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":"6.98"},{"groupId":"OG001","value":"96.3","spread":"11.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":"7.04"},{"groupId":"OG001","value":"95.7","spread":"10.9"}]}]}]},{"type":"SECONDARY","title":"Stanford Sleepiness Scale (SSS) Score on Days 0, 14, and 168","description":"Patient reported outcome on Stanford Sleepiness Score (SSS) administered prior to starting and within 2 hours after ocrelizumab (OCR) infusion, may be completed via phone. SSS measures sleepiness at specific times in a day. Participants will use a scale from 1 to 7 best representing their level of perceived sleepiness. The higher the score, the sleepier the subject and a lower score indicates the alertness of the subject.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.11","spread":"1.27"},{"groupId":"OG001","value":"1.90","spread":"0.876"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.13","spread":"1.13"},{"groupId":"OG001","value":"2.00","spread":"0.667"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.50","spread":"0.837"},{"groupId":"OG001","value":"2.33","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"Visual Analog Scale for Fatigue (VAS-F) Score on Days 0, 14 and 168","description":"Patient reported outcomes on Visual Analog Scale for Fatigue, administered prior to starting and within 2 hours after ocrelizumab (OCR) infusion, may be completed via phone. The scale consists of various items relating to the participants' experience of fatigue and energy. Fatigue subscale ranges from 0-10 and a higher the score represents a greater fatigue for the participant. Energy subscale ranges from 0-10 and a higher the score represents a greater energy as perceived by the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.10","spread":"2.19"},{"groupId":"OG001","value":"1.92","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.20","spread":"1.35"},{"groupId":"OG001","value":"6.28","spread":"2.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.95","spread":"1.94"},{"groupId":"OG001","value":"1.94","spread":"1.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.63","spread":"1.98"},{"groupId":"OG001","value":"6.08","spread":"1.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.52","spread":"1.08"},{"groupId":"OG001","value":"2.12","spread":"2.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.33","spread":"2.66"},{"groupId":"OG001","value":"5.82","spread":"2.43"}]}]}]},{"type":"SECONDARY","title":"Modified Fatigue Impact Scale (MFIS) Score on Day 168","description":"Modified Fatigue Impact Scale (MFIS) administered after the 2nd dose of OCR. Subject answers 21 questions (9 physical, 10 cognitive, and 2 psychological items) related to fatigue in the past 4 weeks with choices of frequency: 0: Never, 1: Rarely, 2: Sometimes, 3: Often, or 4: Almost always. The total MFIS score ranges from 0 to 84. A higher total score represents greater fatigue as perceived by the participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":"15.9"},{"groupId":"OG001","value":"18.3","spread":"22.2"}]}]}]},{"type":"SECONDARY","title":"Multiple Sclerosis Impact Scale (MSIS-29) Score on Day168","description":"Multiple Sclerosis Impact Scale (MSIS-29) is administered after the 2nd dose of ocrelizumab (OCR) infusion to evaluate the physical and psychological impact of multiple sclerosis (MS). Participants rate their symptoms related to MS as 1-Not at all, 2-a little 3-Moderately or 4-Extremely on the two subscales, 20-item physical subscale and 9-item psychological subscale. The two subscales are scored by summing the responses across items, then converting to a 0-100 scale using a formula. For both subscales, higher scores indicate higher impact of MS or greater disability for the participant.\n\nFormula for physical impact subscale score: (100\\*(observed score-20))/ (100-20) Formula for psychological impact subscale score: (100\\*(observed score 9))/ (45-9)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"25.7"},{"groupId":"OG001","value":"6.38","spread":"9.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"10.2"},{"groupId":"OG001","value":"12.3","spread":"14.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Infusion-related reaction","Infusion-related reaction","Infusion-related reaction"]}}}